•  
  •  
 

Abstract

This review article explores the link between progestogens and meningioma risk and outlines the biological mechanisms that may contribute to tumorigenesis. Two progestogens are emphasized through the paper: cyproterone acetate and medroxyprogesterone acetate (Depo-Provera). An important French study examining the relationship between progestogens use and meningioma risk is discussed, along with the health risks associated with long-term use. Additionally, this review advocates for increased routine prescriber-patient consultations and stronger drug regulation to educate and protect patients, particularly those experiencing socioeconomic disadvantages. It is important to note that the FDA recently updated the label for injectable medroxyprogesterone acetate in December 2025 to include a meningioma warning. Furthermore, continued efforts to promote clear and comprehensive drug labeling remain vital.


Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.